Stay updated on Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.

Latest updates to the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.4.2 was added. The lapse-in-funding notice and the earlier Revision: v3.4.1 entry were removed from the page.SummaryDifference0.4%

- Check9 days agoChange DetectedA site-wide notice about a lapse in government funding stating that information may not be up to date has been added, and the page revision indicator updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check17 days agoChange DetectedAdded a glossary toggle and standardized capitalization for several labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data). The revision also updates the version to v3.4.0.SummaryDifference0.2%

- Check31 days agoChange DetectedRevision: v3.3.4 is now displayed, replacing Revision: v3.3.3; this appears to be a maintenance update without changes to study content or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page now shows a Locations section with sites in Massachusetts, Minnesota, New York, and Washington. The HHS Vulnerability Disclosure link has been removed.SummaryDifference0.6%

- Check81 days agoChange DetectedThe page now displays a new revision label, changing from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Daratumumab in Waldenström Macroglobulinemia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Waldenström Macroglobulinemia Clinical Trial page.